---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034668"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:04:05.683842+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Clene reports Q3 net loss of $8.0M; cash $14.6M; awaits FDA meeting on accelerated ALS approval

## Summary
- Met with FDA on Nov 1 to discuss accelerated approval pathway for CNM-Au8 in ALS; awaiting meeting minutes.
- Cash, cash equivalents and marketable securities of $14.6M as of Sep 30, 2024, down from $35.0M at Dec 31, 2023.
- Raised $7.3M in October registered direct offering and private placements; runway extended into Q1 2025.
- Amended Avenue debt facility to defer principal payments and extend maturity to Q2 2025.
- Q3 2024 net loss $8.0M ($1.22 per share) vs net loss $2.4M ($0.38 per share) in Q3 2023.

## SEC filing metadata
- accession: 0001437749-24-034668
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774924034668/0001437749-24-034668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774924034668/clnn20240813_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034668
- JSON: https://secwatch.observer/filing/0001437749-24-034668.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034668.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.